Dr. Jacqueline Lui, Managing Director of Eagle IP Limited, gave a talk on “IP Fundamental” at the Hong Kong Science and Technology Parks.
我們過去活動
Recommended Insights
Breaking: China Released New Implementation Measures for the New Patent Linkage System
2021年7月14日On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]
閱讀更多 >
Inventive Step for an Enantiomer over a Racemate: “L-ornidazole” Patent Invalidation Case
2023年11月27日Each year, China’s Supreme People’s Court (SPC) issues its annual “Judgment Digests”, which includes a list of “48 typical cases” highlighting representative SPC decisions in the previous year. The Judgment Digests help us understand more about the SPC’s judicial ideology, trial concepts, and adjudication methods in dealing with difficult and sophisticated legal issues as well […]
閱讀更多 >
Can I transfer priority rights in China without the consent of other applicants? Insights from the Broad Institute’s CRISPR patent
2025年2月4日The high-profile disputes surrounding an important CRISPR patent belonging to The Broad Institute, MIT and Harvard (hereinafter “the proprietors”) has attracted a lot of attention in recent years, particularly regarding the validity of priority rights that were challenged worldwide. In Europe, the patent was famously revoked by the European Patent Office (hereinafter “EPO”) due to […]
閱讀更多 >
China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)
2021年4月29日This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]
閱讀更多 >